Prolia (denosumab) is a prescription drug that’s used to treat osteoporosis and bone loss. Prolia comes as a liquid solution that’s given as an injection under the skin. Prolia is prescribed for ...

Prolia is a monoclonal antibody that binds to a specific protein on osteoclasts and decreases their activity. Osteoclasts are responsible for dissolving and breaking down old or damaged bone cells. By ...

Prolia (denosumab) can cause side effects that range from mild to serious. Examples include joint pain and tooth and jaw-related side effects. If side effects from Prolia become difficult to tolerate, ...

On November 24, 2025, Alvotech announced that the European Commission (EC) has approved AVT03 as a biosimilar to Amgen’s PROLIA® and XGEVA® (denosumab) in the European Economic Area. AVT03 is approved ...

Credit: Fresenius Kabi. Conexxence and Bomyntra were approved by the FDA in March 2025. The interchangeability designation allows the biosimilars to be substituted for the reference product at the ...